#Clinical Trials #Florida Cancer Specialists #Blood Cancer

Florida Cancer Specialists: Innovating Blood Cancer Treatments through Research

Florida Cancer Specialists & Research Institute (FCS) is paving the way for advancements in the treatment of blood cancers, marking a significant stride in healthcare innovation. As a leading provider of comprehensive cancer care, FCS is dedicated to improving patient outcomes and knowledge within the field through rigorous research and clinical trials.

Recently, FCS played a notable role at the prestigious American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego. This gathering is recognized as the world's largest hematology event, convening top experts in the field to share groundbreaking research findings and treatments. FCS showcased its involvement in early-phase clinical trials that represent the future of therapy for various hematologic conditions.

Dr. Manish Patel, the Director of Drug Development at FCS, expressed the importance of their research: “It is especially gratifying to participate in transformative research that is advancing the next generation of therapies for hematologic conditions.” His leadership oversees three dedicated drug development units within the practice, enabling access to over 130 clinical trials for patients at any given time.

Among the notable advancements, FCS was the first to administer revumenib, an innovative treatment recently approved by the U.S. Food and Drug Administration (FDA) for relapsed or refractory acute leukemia. This approval marks a historic progression in cancer treatment, providing hope for many patients.

At the ASH event, several impactful abstracts authored by FCS hematologists and oncologists were presented:

• - Dr. Manish Patel discussed the Phase Ib study of PRT543, a protein arginine methyltransferase inhibitor, targeting relapsed or refractory myeloid malignancies.
• - Dr. Syed Zafar focused on the effectiveness of belantamab mafodotin combined with pomalidomide versus other established protocols in treating multiple myeloma.
• - Dr. Alexander Philipovskiy presented a trial involving the innovative subcutaneous delivery of isatuximab in conjunction with standard therapies for multiple myeloma.

Additionally, the FCS Real-World Evidence (RWE) team is also making significant contributions. Their study titled